- Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCondition: Pediatric Growth Hormone Deficiency
Interventions: Drug: MOD-4023; Drug: Somatropin
Sponsors: Prolor Biotech, Inc.; Prolor Biotech, Inc.
Recruiting - verified May 2012 - Condition: Infertility
Interventions: Drug: Prednisolone and Heparin during COH for IVF; Drug: COH for IVF
Sponsors: National and Kapodistrian University of Athens; National and Kapodistrian University of Athens
Recruiting - verified May 2012 - Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either 500 mg of Ciprofloxacin (oral); Drug: or 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified May 2012 - Condition: Acne Vulgaris
Interventions: Device: KLOX Biophotonic System; Other: No treatment
Sponsors: KLOX Technologies Inc.; KLOX Technologies Inc.
Recruiting - verified April 2012 - Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation
Sponsors: Novartis; Novartis Pharmaceuticals
Available - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: taxane
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Pneumococcal Disease
Intervention: Other: Non Intervention
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified April 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 30; Drug: sitagliptin; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified May 2012 - Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Drug: Bendamustine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir + peginterferon alfa + ribavirin; Drug: peginterferon alfa + ribavirin; Drug: peginterferon alfa + ribavirin
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Available - verified April 2012 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2012 - Conditions: Haemophilia; Haemophilia A
Intervention: Drug: NNC 0155-0000-0004
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: TMC435; Drug: TVR
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Acute Respiratory Distress Syndrome
Interventions: Device: Lung protective CMV; Device: HFO-RMs
Sponsors: University of Athens; University of Athens; University of Thessaly
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Placebo matching BMS-790052; Drug: Pegylated-interferon alfa 2a; Drug: Pegylated-interferon alfa 2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Thrombocytopaenia
Interventions: Drug: eltrombopag; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: QAW039; Drug: Comparator leukotriene receptor antagonist (LRTA); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Transfusion-dependent β-thalassemia Patients; Cardiac Iron Overload
Interventions: Drug: Deferasirox; Drug: Deferasirox + Deferoxamine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Interventions: Drug: NNC 0078-0000-0007; Drug: eptacog alfa (activated)
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012 - Condition: Chronic Hepatitis
Interventions: Drug: oral antiviral for HBV; Drug: tenofovir disoproxil fumarate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: MDS
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212; Drug: docetaxel
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Cerebrospinal Fluid Leaks
Interventions: Procedure: TachoSil®; Procedure: Current Practice
Sponsors: Nycomed; Nycomed
Recruiting - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Cell
Interventions: Drug: Afatinib; Drug: Methotrexate; Drug: Methotrexate
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Pulmonary Fibrosis
Interventions: Drug: placebo; Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Atherosclerosis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Roflumilast; Drug: Placebo
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Other: Best Supportive Care; Drug: Panitumumab
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Ventilator-associated Bacterial Pneumonia
Interventions: Drug: Colistin; Drug: Meropenem
Sponsors: Spanish Clinical Research Network - CAIBER; Spanish Clinical Research Network - CAIBER; European Commission
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: Best Supportive Care
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified May 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: bortezomib; Other: randomization to study procedures only
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: Placebo; Drug: Placebo; Drug: methotrexate; Drug: folate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Schizophrenia
Intervention: Drug: Paliperidone Palmitate
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Multiple Sclerosis Relapse
Interventions: Drug: Teriflunomide (HMR1726); Drug: Matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: carboplatin; Drug: Paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012 - Conditions: Influenza A Virus, H1N1 Subtype; Influenza, Human; Influenza B Virus; Influenza, Seasonal
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Intervention: Drug: panitumumab
Sponsors: Hellenic Cooperative Oncology Group; Hellenic Cooperative Oncology Group
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Cardiomyopathies, Primary; Arrhythmia; Sudden Cardiac Death; Calcium Metabolism Disorders
Intervention:
Sponsors: University Medical Center Goettingen; University Medical Center Goettingen; UMC Utrecht; Katholieke Universiteit Leuven; University of Glasgow; University of Athens
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Mabthera intravenous; Drug: MabThera subcutaneous
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Pain
Intervention: Drug: Oxycodone HCl controlled-release tablets
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified May 2012 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Myocardial Infarction
Interventions: Drug: Eplerenone; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Hypertension, Resistant to Conventional Therapy; Atrial Fibrillation
Interventions: Procedure: Circumferential PV isolation; Procedure: Circumferential PVI+renal denervation
Sponsors: Meshalkin Research Institute of Pathology of Circulation; Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified April 2012 - Condition: Fracture Healing
Interventions: Drug: Placebo; Drug: AMG 785 140 mg; Drug: AMG785 70mg; Drug: AMG 785 210mg
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673); Drug: Otamixaban matching placebo; Drug: Unfractionated Heparin; Drug: Unfractionated Heparin matching placebo; Drug: Eptifibatide; Drug: Eptifibatide matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Intra-Abdominal Infection
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Leukemia, Myeloid
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: No Intervention
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.; Merck
Recruiting - verified April 2012 - Condition: Partial Epilepsy
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsors: Bial - Portela C S.A.; Bial - Portela C S.A.; Sunovion
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium +salmeterol+ fluticasone high dose; Drug: Tiotropium+salmeterol+ fluticasone high,med, low, placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Fracture Healing
Interventions: Drug: AMG 785 210mg; Drug: AMG 785 70mg; Drug: AMG 785 140 mg; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Hemophilia A
Interventions: Drug: moroctocog alfa (AF-CC) (ReFacto AF); Procedure: Laboratory tests
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Mantle Cell Lymphoma; Relapsed or Refractory Mantle Cell Lymphoma
Interventions: Drug: Lenalidomide; Drug: Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Metastatic Breast Cancer; Metastases, Brain
Interventions: Drug: capecitabine; Drug: lapatinib; Drug: trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Hypertension, Pulmonary
Intervention: Drug: ambrisentan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Myocardial Infarction
Interventions: Drug: tenecteplase; Drug: enoxaparin; Drug: clopidogrel; Procedure: catheterisation; Procedure: primary PCI
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012 - Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Bosentan; Drug: Sildenafil Citrate
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012
 |
Join Clinical Trials that are held in Athens,Greece |
Clinical Trial Locations 